Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 49 of 114, showing 5 Applications out of 567 total, starting on record 241, ending on 245

# Protocol No Study Title Investigator(s) & Site(s)

241.

ECCT/14/09/04  
    Assessment of Safety and Efficacy of Brozedex Syrup in the Treatment of Productive Cough. Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel Group and Multi-Site Study Conducted In Nairobi in three sites    
Principal Investigator(s)
1. Hudson Aubrey Lodenyo
Site(s) in Kenya
1. Rhodes Clinic/Ngaira Health Centre (Nairobi City county)
2. Mbagathi District Hospital (Nairobi City county)
3. Mama Lucy Hospital (Nairobi City county)
 
View

242.

ECCT/19/06/02   The A-PLUS study
    Prevention of Maternal and Neonatal Death/Infections with a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-Income Countries): a Randomized Controlled Trial   
Principal Investigator(s)
1. Prof Fabian Esamai Omoding Esamai
Site(s) in Kenya
1. Alupe, Sirisia, Bokoli (Bung\'oma county)
2. Nambale, Nasewa, Lukolis, Khunyangu (Busia county)
3. Mumias (Kakamega county)
 
View

243.

ECCT/21/10/03   Validation of Chloe SED
    Validation of Chloe SED, a reusable, low-cost syringe extension device for the provision of paracervical analgesia during gynecologic procedures    
Principal Investigator(s)
1. Stephen Gwer
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county)
2. Kisii Teaching & Referral Hospital (KTRH) (Kisii county)
 
View

244.

ECCT/25/05/11   Sparkle study site-1406
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View

245.

ECCT/25/05/01   Sparkle Study Site 1403
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View